Javier Martin-Broto: The highest RECIST activity with pazopanib in the sarcoma space, brilliantly put together by Carlos Torrado
Javier Martin-Broto, Sarcoma Medical Oncologist at the University Hospital Jiménez Díaz Foundation, shared an article by Carlos Torrado, et al. on LinkedIn:
“Pazopanib’s activity in Malignant Granular Cell Tumors is showing some serious promise, with a response rate of 40% based on RECIST criteria and an 80% disease control rate.
That’s a big deal—actually, it’s the highest RECIST activity we’ve seen with pazopanib in the sarcoma space.
Given that this is an ultra-rare disease, I think it’s worth getting the word out about this compilation brilliantly put together by Dr. Carlos Torrado, now at MD Anderson Cancer Center in Houston, Texas.”
Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature.
Journals: Cancers by MDPI
Authors: Carlos Torrado, et al.
More posts featuring Javier Martin-Broto.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023